Compare Medpace Holdings Inc (MEDP) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Starbucks Corp — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 6.3× Medpace Holdings Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Starbucks Corp for 190 Days on average.
| MEDP | SBUX | |
|---|---|---|
Market Cap | $16.82B | $106.26B |
Volume | 223,093 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $108.55 |
52-Week Low | $393.42 | $78.46 |
Typical Hold Time | 14 Days | 190 Days |
Enterprise Value | $16.44B | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Starbucks (SBUX) trades at $93.21, down 0.4% on the day, amid a bearish technical signal and recent store closure announcements. The stock shows mixed earnings performance with Q1 and Q2 2026 beats but a Q4 2025 miss, while 2025 revenue grew to $37.18B with a net income margin of 5.17%. Analyst consensus is a Buy with a $115.50 price target, but technical indicators suggest near-term pressure with support at $89 and resistance at $96.
The outlook for SBUX hinges on its turnaround strategy execution, including portfolio optimization through store closures. Upside potential exists from analyst targets, but risks include labor relations, competitive pressures, and macroeconomic sensitivity. The stock's high P/E of 53.88 indicates growth expectations must be met for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
